TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07847411: A Multi-center, Open-label Study to Evaluate the Safety and Efficacy of Velaglucerase Beta Enzyme Replacement Therapy in Children With Gaucher Disease

Sponsor: CANbridge Life Sciences Ltd. · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$23,401,600

Rescue Site Savings

+$15,430,430

Unlock Full NCT07847411 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07847411 Rescue Dossier →